Seroepidemiological Study of SARS-CoV-2 (COVID-19) Infection in Population Subgroups in the State of São Paulo

February 14, 2024 updated by: Butantan Institute

Seroepidemiological Study of SARS-CoV-2 Infection in Population Subgroups in the State of São Paulo

Seroepidemiological Study of SARS-CoV-2 Infection in Population Subgroups in the State of São Paulo

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This is a cross-sectional study to estimate the prevalence of antibodies against SARS-CoV-2 is different population subgroups in the State of São Paulo

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
18901

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Brazil
      • Sao Paulo, Brazil, 05503-900
        • Avenida Vital Brasil 1500

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

6 months to 100 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

  • Home contacts of health professionals at the Hospital das Clínicas of the Medical School of USP diagnosed with COVID-19;
  • Refugees living in the city of São Paulo - CORAS-BR Project;
  • Blood Donors of the Fundação Pró-Sangue Hemocentro de São Paulo
  • Butantan Penitentiary Progression Center participants;
  • Penitentiary System Hospital Center (CHSP) participants;
  • SABE Project - Cohort of the Elderly in the city of São Paulo and their home contacts;
  • Residents of the Long Term Care Institution (ILPI) of Botucatu;
  • Home contacts of children and adolescents with a positive diagnosis for COVID-19, attended at Instituto da Criança, HCFMUSP.

Description

Inclusion Criteria:

  • All potential volunteers invited to participate in the study.

Exclusion Criteria:

  • All potential eligible participants, but who do not show interest in participating in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
HC-USP
Home contacts of health professionals diagnosed with COVID-19 at the Hospital of Clínic of Medicine School of the University of São Paulo
Diagnostic test: Serological test
IgM and IgG for SARS-CoV-2
Diagnostic test: Nasopharyngeal Swab
PCR for SARS-CoV-2
Diagnostic test: Oropharyngeal Swab
PCR for SARS-CoV-2
CORAS
Refugees living in the city of São Paulo
Diagnostic test: Serological test
IgM and IgG for SARS-CoV-2
Diagnostic test: Nasopharyngeal Swab
PCR for SARS-CoV-2
Diagnostic test: Oropharyngeal Swab
PCR for SARS-CoV-2
Hemocenter
Blood Donors of the Pró-Sangue Hemocenter Foundation of São Paulo
Diagnostic test: Serological test
IgM and IgG for SARS-CoV-2
CPP - Butantan Penitentiary Progression Center
Participants of the CPP - Butantan Penitentiary Progression Center
Diagnostic test: Serological test
IgM and IgG for SARS-CoV-2
Diagnostic test: Nasopharyngeal Swab
PCR for SARS-CoV-2
Diagnostic test: Oropharyngeal Swab
PCR for SARS-CoV-2
CHSP - Penitentiary System Hospital Center
Participants of the CHSP - Penitentiary System Hospital Center
Diagnostic test: Serological test
IgM and IgG for SARS-CoV-2
Diagnostic test: Nasopharyngeal Swab
PCR for SARS-CoV-2
Diagnostic test: Oropharyngeal Swab
PCR for SARS-CoV-2
SABE (Health, Wellness and Aging)
Participants of the SABE Project (Health, Wellness and Aging)
Diagnostic test: Serological test
IgM and IgG for SARS-CoV-2
Diagnostic test: Nasopharyngeal Swab
PCR for SARS-CoV-2
Diagnostic test: Oropharyngeal Swab
PCR for SARS-CoV-2
ILPI - Long-Term Care Institution for the Elderly
Residents of the Long-Term Care Institution for the Elderly of Botucatu
Diagnostic test: Serological test
IgM and IgG for SARS-CoV-2
Diagnostic test: Nasopharyngeal Swab
PCR for SARS-CoV-2
Diagnostic test: Oropharyngeal Swab
PCR for SARS-CoV-2
ICR-USP - Children's Institute of HCFMUSP
Home contacts of children and adolescents diagnosed with COVID-19, attended at the Children's Institute of HCFMUSP
Diagnostic test: Serological test
IgM and IgG for SARS-CoV-2
Diagnostic test: Nasopharyngeal Swab
PCR for SARS-CoV-2
Diagnostic test: Oropharyngeal Swab
PCR for SARS-CoV-2

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Prevalence of antibodies against SARS-CoV-2 through serological testing
Time Frame: 1 month
IgM and IgG antibodies against SARS-CoV-2
1 month
Frequency of participants with a positive RT-PCR test result for SARS-CoV-2
Time Frame: 1 month
Positive RT-PCR test result for SARS-CoV-2
1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Butantan Institute

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Chair: Alexander R Precioso, MD, PhD, Instituto butantan

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 1, 2020

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 15, 2020

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 30, 2020

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 22, 2020

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 27, 2020

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 29, 2020

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
February 15, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 14, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
February 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • COVID-19-Epi-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on SARS-CoV 2

Clinical Trials on Serological test

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings